Novel non-selective cation channel in neuronal cells and method for treating brain swelling

Abstract

The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This Application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 60 / 365,933 filed on Mar. 20, 2002, to U.S. Provisional Application Ser. No. 60 / 610,758 filed Sep. 18, 2004, and to U.S. Provisional Patent Application Ser. No. 60 / 698,272 filed on Jul. 11, 2005, and is a continuation-in part of, and claims priority under 35 U.S.C. § 120, to U.S. Non-Provisional application Ser. No. 10 / 391,561, filed on Mar. 20, 2003, and U.S. Non-Provisional application Ser. No. 11 / 229,236, filed Sep. 16, 2005, all of which provisional and non-provisional applications are hereby incorporated herein by reference in their entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made in part with government support under Grant No. NSO48260 awarded by the National Institutes of Health, a grant awarded by the Heart Lung and Blood Institute (HL082517), and a Merit Review grant from th...

AI Technical Summary

Problems solved by technology

Injury to the nervous system has serious consequences.

Swelling of neural cells is part of the cytotoxic or cell swelling response that characterizes brain damage in cerebral ischemia and traumatic brain injury, and is a major cause of morbidity and mortality.

Cytotoxic edema is a well-recognized phenomenon clinically that causes brain swelling, which worsens outcome and increases morbidity and mortality in brain injury and stroke.

By contrast, in necrotic cell death, the plasma membrane is ruptured, causing cytosolic contents to be released and thereby triggering tissue inflammation.

Necrotic cell death may be more deleterious to nearby viable tissues, given the secondary inflammatory damage that is initiated.

Inhibition of ATP synthesis or ATP depletion also causes neural cell swelling, blebbing and, if sufficiently severe, plasma membrane disruption and cell death.

However, an equivalent degree of osmotic swelling induced by ouabain-mediated inhibition of the Na+ / K+-ATPase pump in neural cells does not produce large depolarization, blebbing or cell death.

None of these studies have identified the cellular mechanism instrumental in the cell swelling that is associated with brain damage in cerebral ischemia and traumatic brain injury and spinal cord injury.

On the other hand, the gliotic capsule forms a potentially harmful mass of tissue from which originates edema fluid that contributes to brain swelling, and whose constituent cells undergo cytotoxic edema, which adds further to brain swelling.

Images